Webinar: MyD88 signaling in intestinal epithelial cells shapes the composition of the gut microbiota

  Attend a 30 minute webinar with Dr. Charlotte Kaetzel from the University of Kentucky School of Medicine on “MyD88 signaling in intestinal epithelial cells shapes the composition of the gut microbiota.” Dr. Kaetzel and colleagues have identified major microbiome composition changes in the intestine of mice with a deletion in the critical signaling molecule involved [...]

The Microbiome: Keystone Symposia Quick Recap

This spring, the Keystone Symposia meeting on The Microbiome at the Keystone Resort in Colorado was host to a fantastic collection of speakers and posters focused on understanding the mechanisms underpinning the host-microbiota relationship and how they impact health and disease. There were several key themes that sparked our interest here at Second Genome. Significant [...]

New Publication on Signature of Intestinal Barrier Loss

Second Genome’s Microbiome Signature Discovery services have been cited in a new publication in the prestigious journal Mucosal Immunology. The Kaetzel laboratory at the University of Kentucky College of Medicine  found that major microbiome composition changes occurred in the intestine of mice with a deletion of a critical signaling molecule involved in maintaining the intestinal [...]

Second Genome Announces Expansion of Scientific Advisory Board

Second Genome today announced the expansion of our Scientific Advisory Board. Our preeminent board of leaders in the genomic technologies and microbiome space now includes: Dr. Gary Andersen, Dr. Martin Blaser, Dr. Michael Fischbach, Dr. Susan Lynch, Dr. Pankaj Jay Pasricha, Dr. David Relman, and Dr. Justin Sonnenburg. Read more about our advisors.

Second Genome Announces New SVP of Corporate Development

Second Genome welcomes Mohan S. Iyer to the team. As SVP of Corporate Development, Mohan is responsible for building relationships and working with our partners, including biopharma and nutrition companies, to identify novel biomarkers for classifying patient populations and to assess the impact of novel microbiome-modulating products. Mohan has over 25 years experience in the life [...]

Second Genome Has New Headquarters

Second Genome’s offices have moved (but we’re still only a phone call or email away!). Our new address is: 1150 Bayhill Drive, Suite 215 San Bruno, CA 94066 650.440.4606 For general inquiries please email info@secondgenome.com.

Second Genome Welcomes Bioinformaticist, Justin Kuczynski

Second Genome is pleased to welcome Justin Kuczynski, Ph.D. to our bioinformatics team. Justin studied physics as an undergraduate at Stanford University. He then joined the Molecular, Cellular, and Developmental Biology department at the University of Colorado in Boulder, where he completed his thesis research in Rob Knight’s group. He is also one of the [...]

Second Genome Announces Series A Financing

ATV, Morgenthaler co-lead investment in company leveraging the microbiome for personalized medicine solutions SAN FRANCISCO, CA – August 9, 2011 – Second Genome, Inc., the microbiome company, announced today that it has closed a Series A investment co-led by new investors Advanced Technology Ventures (ATV) and Morgenthaler Ventures, and including previous investors Wavepoint Ventures, Seraph [...]

We’re Hiring: VP-Corporate Development

Vice President, Corporate Development Job Description: Second Genome, Inc., an innovative venture-backed start-up in the Bay Area, is leveraging the microbiome to develop personalized medicine solutions. We are looking for a great Vice President of Corporate Development with a strong blend of scientific understanding and business acumen, an accomplished history of sourced and implemented partnerships [...]

Novel Biomarkers of Radiation Exposure

Researchers led by Dr. John Baker, at the Medical College of Wisconsin, have used Second Genome’s Microbial Profiling Services to uncover a novel microbial biomarker of prior radiation exposure which could be used to triage patients in the event of a nuclear disaster. In the following interview with Second Genome, Dr. Baker describes the technical [...]